Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Agilent Reports Third-Quarter Results

Published: Thursday, August 15, 2013
Last Updated: Thursday, August 15, 2013
Bookmark and Share
Revenues were $1.65 billion for the third fiscal quarter ended July 31, 2013, down 4 percent over one year ago.

Agilent reported orders of $1.60 billion, down 4 percent compared with one year ago. Third-quarter GAAP net income was $168 million, or $0.49 per share. Last year's third-quarter GAAP net income was $243 million, or $0.69 per share.

During the third quarter, Agilent had intangible amortization of $48 million and integration and transformation costs of $14 million. Excluding these items and $3 million of other net charges, Agilent reported third-quarter adjusted net income of $233 million, or $0.68 per share.

Agilent CEO Bill Sullivan said, "Although we are operating in a very challenging economic environment, we are pleased with our operational performance, as we continue to make progress improving our manufacturing efficiency and streamlining our expense structure. The result has been better than forecasted operating margins."

Electronic Measurement third-quarter revenues were down 17 percent compared with the prior year, with continuing weakness in wireless manufacturing. Operating margins were 18 percent.

Chemical Analysis revenues were up 1 percent compared with a year ago, led by growth in food and energy markets. Operating margins were 22 percent.

Life Sciences revenues were up 3 percent over a year ago, with strength in pharmaceutical end-markets. Operating margins were 17 percent.

Diagnostics and Genomics revenues grew 54 percent, up 6 percent adjusting for the effects of the Dako acquisition. Operating margins were 15 percent.

Agilent generated $215 million of cash from operations in the quarter. Third-quarter ROIC was 15 percent(3).

Fourth-quarter 2013 revenues are expected to be in the range of $1.7 billion to $1.72 billion. Fourth-quarter non-GAAP earnings are expected to be in the range of $0.75 to $0.77 per share.

For the full fiscal year 2013, Agilent expects revenue of $6.76 billion to $6. 78 billion and non-GAAP earnings of $2.83 to $2.85 per share.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Names CNAG as Certified Provider of Target-Enrichment Services
Centro Nacional de Análisis Genómico (CNAG) in Barcelona is one of Europe’s leading genome analysis centers.
Monday, February 23, 2015
Agilent to Close NMR Business
The announcement is part of Agilent's strategy to address the business shortfalls of its Research Products Division.
Wednesday, October 15, 2014
Agilent Technologies, University of Toronto to Collaborate on Metabolomics MRM Library-Software Solution
Scientists will be provided with a robust LC/MS solution to accelerate cell biology, disease research.
Tuesday, September 30, 2014
Agilent, Seoul National University to Collaborate on New Research Center
The facility will support new drug development center in the university's college of pharmacy.
Tuesday, May 13, 2014
Agilent Introduces Enhanced Electronic Laboratory Notebook
OpenLAB ELN integrates scientific results from multiple analytical software applications, quickly and easily.
Tuesday, November 19, 2013
Agilent and Daegu Gyeongbuk Institute of Science and Technology Collaborate
Neurometabolomics Center will use Agilent's bio-analytical instruments in research of biomarkers for early detection and diagnosis of brain diseases.
Friday, November 01, 2013
Agilent Combines Its Life Sciences and Diagnostics Businesses
Decision follows Agilent's announcement that it plans to separate the company into two independent publicly traded companies.
Thursday, September 19, 2013
Agilent to Acquire Assets from ABC Instrumentación Analítica
The companies have signed a definitive agreement for Agilent to acquire assets from the privately held Mexican distributor.
Thursday, September 05, 2013
Agilent Technologies Triple Quadrupole ICP-MS Selected for R&D 100 Award
These prestigious awards recognize the 100 most technologically significant products introduced into the marketplace over the past year.
Monday, July 15, 2013
Agilent to Host Forensics Webinar
The webinar, which will be held on June 20, will focus on LC/MS/MS methods for cannabinoid and benzodiazepine quantitation in whole blood samples.
Wednesday, June 05, 2013
Agilent Technologies Opens New X-ray Diffraction Manufacturing Facility
The state-of-the-art facility in Wroclaw, Poland gives Agilent significantly greater manufacturing capacity and enhanced R&D capabilities compared with the company's old facility.
Wednesday, November 21, 2012
Agilent Technologies Reports Fourth-Quarter 2012 Results
Revenues for the fourth fiscal quarter ended October 31, 2012 were $1.77 billion, up 2 percent one year ago.
Tuesday, November 20, 2012
2011 Russell Varian Prize for Innovation in Nuclear Magnetic Resonance
Agilent Technologies Inc. announces Gareth Alun Morris, professor of physical chemistry at the University of Manchester, as the winner of the 2011 Russell Varian Prize.
Friday, September 30, 2011
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Fat Cells Originating from Bone Marrow Found in Humans
Cells could contribute to diabetes, heart disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos